Saving Beta-Cells, Improving Lives
We develop a novel therapy to reverse the progression of early-stage type 1 diabetes and reduce insulin dependency.
​
From wildcrafting
to bench-to-bedside development.
Dunica was founded by Daniella Givon, a clinical herbalist and entrepreneur whose daughter was diagnosed with type T1 diabetes at the age of seven years. They were quickly familiarized with the struggle of managing the disease, juggling a strict diet, blood-sugar monitoring, and multiple insulin injections taken day and night.
What makes our therapy unique?
Provide a general description of the items below and introduce the services you offer. Click on the text box to edit the content.
Sustainable
Source
Formulated from the next generation of phytochemicals
Small-Molecule
Structure
Enhanced efficacy through better tissue permeability
Immunomodulating
Therapy
Better safety profile and reduced risk of inflammation
Designed for Oral Consumption
Improved patient experience - No injections needed
Why do experts support our mission?
"DUN T1 seems to be the ideal product to improve the future treatment of Type 1 Diabetes."
Dr. Ulrike Hostalek, Executive Medical Director Head of GMA MU CM&E
Milestons to date
2019
Establishment, In vivo-preclinical safety and efficacy research, F&F fundraising
2020
Stabilizing a raw material source - Domestication of selected botanical strain
2021
Finalization of pre-clinical Proof of Concept, expanding research team
2022
Granted 2 research grants from the pharmaceutical company (Germany)
2023
Mechanism in-vitro study, Granted research grant from the pharmaceutical company
2024
Finalizing development process, First in human clinical study
